Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Starinsky
The Ras Inhibitor Farnesylthiosalicylic Acid as a Potential Therapy for Neurofibromatosis Type 1
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Inhibition of Contact Sensitivity by Farnesylthiosalicylic Acid-Amide, a Potential Rap1 Inhibitor
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Suppression of Lung Cancer Tumor Growth in a Nude Mouse Model by the Ras Inhibitor Salirasib (Farnesylthiosalicylic Acid)
Molecular Cancer Therapeutics
Cancer Research
Oncology
Suppression of Survivin Expression in Glioblastoma Cells by the Ras Inhibitor Farnesylthiosalicylic Acid Promotes Caspase-Dependent Apoptosis
Molecular Cancer Therapeutics
Cancer Research
Oncology
Neurofibromatosis Type 1 Alternative Splicing Is a Key Regulator of Ras Signaling in Neurons
Molecular and Cellular Biology
Cell Biology
Molecular Biology
Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Neurofibromatosis Type 1 (NF1)
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer Research
Oncology
Genetics
Hematology
Malignancy in Neurofibromatosis Type 1
Oncologist
Cancer Research
Medicine
Oncology
Health Supervision for Children With Neurofibromatosis Type 1
Pediatrics
Child Health
Pediatrics
Perinatology
Neurofibromatosis Type 1: Modeling CNS Dysfunction
Journal of Neuroscience
Neuroscience
